Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 15/20 | 0.54 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31247612 | 0.81 | CDK1 (0.42) | KMT2AJAK2TYK2ALDH1A1MAPK1 | |
| SCHEMBL31247520 | 0.79 | GRM5 (0.54) | GRM5ASIC3KDM4EJAK1TYK2 | |
| SCHEMBL31247813 | 0.74 | GRM5 (0.58) | GRM5ASIC3KDM4EALDH1A1HTT | |
| SCHEMBL31247652 | 0.72 | GRM5 (0.45) | GRM5ASIC3KDM4EJAK2JAK1 | |
| SCHEMBL25289237 | 0.71 | GAA (0.39) | KDM4EGAAJAK2TYK2ALDH1A1 | |
| SCHEMBL5582792 | 0.71 | GRM5 (1.00) | GRM5ASIC3 | |
| SCHEMBL31247774 | 0.71 | GRM5 (0.84) | GRM5ASIC3KMT2AHTT | |
| SCHEMBL31247691 | 0.70 | TNNI3K (0.42) | GRM5KDM4EJAK2JAK1TYK2 | |
| SCHEMBL31247468 | 0.69 | KDM4E (0.47) | KDM4EJAK2JAK1TYK2JAK3 | |
| SCHEMBL31247545 | 0.68 | EGFR (0.52) | GRM5ASIC3JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719394-A2 | INHIBITORS OF TYK2 | Atomwise Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260048051-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ATOMWISE INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20240425484-A1 | INHIBITORS OF TYK2 | Atomwise Inc. | 2024-12-26 | — | — | US | disclosed |
| WO-2024250010-A2 | INHIBITORS OF TYK2 | Atomwise Inc. (US) | 2024-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048051-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | TYK2, FRK, DYRK2 | GRM5 1437/4885ASIC3 2671/4885KDM4E 642/4885 |
| US-20240425484-A1 | INHIBITORS OF TYK2 | TYK2, LCK, JAK2 | GRM5 2396/4885ASIC3 2980/4885KDM4E 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.